Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.

NCT05345769 is registered in ClinicalTrials.gov with AffaMed Therapeutics Limited as lead sponsor.

NCT NCT05345769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-Center, Open-label, Sequential, Multiple Ascending-Dose and High Concentration Cohorts Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AM712 Following Intravitreal Administration in Patients with Neovascular Age-related Macular Degeneration.
Lead sponsor
AffaMed Therapeutics Limited
Phase
Phase 1
Overall status
Completed
Start date
April 28, 2022
Completion date
November 4, 2024
Enrollment
21 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration